

Expected submission timelines

2022 →		2023 →		2024 →		2025 and beyond →	
Dupixent ^{®A} Prurigo nodularis	Sarclisa [®] 1L Newly Diagnosed MM T1 (IMROZ)	Dupixent ^{®A} Bullous pemphigoid	Keyzara ^{®A} Polyarticular juvenile idiopathic arthritis	Dupixent ^{®A} COPD	tolebrutinib RMS	Keyzara ^{®A} Systemic Juvenile Arthritis	tolebrutinib MG
Dupixent ^{®A} Chronic spontaneous urticaria	efanesoctocog alfa ^B Hemophilia A	Dupixent ^{®A} Chronic Inducible Cold Urticaria	tusamitamab ravtansine 2-3L NSCLC	Dupixent ^{®A} Chronic Sinusitis without Nasal Polyps	Neoviazyme [®] Kemp's Disease Infantile Onset	amlitelimab Atopic Dermatitis	tolebrutinib PPMS
				Dupixent ^{®A} Allergic Fungal Rhinosinusitis	venglustat GM2 gangliosidosis	Dupixent ^{®A} CPUO	tolebrutinib SPMS
				itepekimab ^A COPD	rilzabrutinib ITP	Libtayo ^{®A} adj CSCC	venglustat Gaucher Type 3
				Sarclisa [®] Newly Diagnosed MM Te (GMMG)	fitusiran Hemophilia A/B	Sarclisa [®] 1-2L AML / ALL ped.	venglustat Fabry Disease
				amcenestrant plus palbociclib 1L mBC	MenQuadfi [®] 6w+	Sarclisa [®] Smoldering MM	fitusiran Hemophilia A/B pediatric
						amcenestrant adj breast cancer	VRVg Purified vero rabies vaccine

- Immuno-inflammation
- Oncology
- Neurology
- Rare Diseases
- Rare Blood Disorders
- Vaccines

As of March 31, 2022. For collaborations see slide 52. For abbreviations see slide 53.
Excluding Phase 1 and 2 (without Proof of Commercial Concept); projects within a specified year are not arranged by submission timing.